Sponsored by
AFX News Limited
YM BioSciences US unit enrolls first patient for phase II trial of nimotuzumab
02.13.08, 7:41 AM ET
LONDON (Thomson Financial) - YM BioSciences Inc said its YM BioSciences USA Inc unit has enrolled the first patient in its phase II trial of nimotuzumab in paediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG), a form of inoperable, treatment-resistant brain cancer.
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor, it said.
The oncology company said eight US paediatric clinical centres and two Canadian centres will be participating in the single-arm trial, which is designed to enrol 44 patients with DIPG who will be treated with nimotuzumab as monotherapy.
TFN.newsdesk@thomson.com
kal/am